MX2014002465A - Composiciones acuosas que comprenden arbekacina. - Google Patents

Composiciones acuosas que comprenden arbekacina.

Info

Publication number
MX2014002465A
MX2014002465A MX2014002465A MX2014002465A MX2014002465A MX 2014002465 A MX2014002465 A MX 2014002465A MX 2014002465 A MX2014002465 A MX 2014002465A MX 2014002465 A MX2014002465 A MX 2014002465A MX 2014002465 A MX2014002465 A MX 2014002465A
Authority
MX
Mexico
Prior art keywords
arbekacin
aqueous compositions
compositions
provides
aerosolized
Prior art date
Application number
MX2014002465A
Other languages
English (en)
Other versions
MX357556B (es
Inventor
Michael Hahn
Yukihiro Yagi
Toshie Sugano
Kuniko Shoji
Nao Sano
Manfred Keller
Roman Egle
Masashi Tanaka
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of MX2014002465A publication Critical patent/MX2014002465A/es
Publication of MX357556B publication Critical patent/MX357556B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Abstract

La invención proporciona composiciones farmacéuticas líquidas acuosas que comprenden arbekacina e iones cloruro. Las composiciones son bien tolerables para el uso en un método para el tratamiento o prevención de una enfermedad del tracto de respiratorio superior e inferior, en donde la composición se forma en aerosol y se inhala por el paciente. Además, la invención proporciona clorhidrato de arbekacina.
MX2014002465A 2011-09-12 2012-08-03 Composiciones acuosas que comprenden arbekacina. MX357556B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11180927.3A EP2567691B1 (en) 2011-09-12 2011-09-12 Aqueous compositions comprising arbekacin
PCT/EP2012/065265 WO2013037566A1 (en) 2011-09-12 2012-08-03 Aqueous compositions comprising arbekacin

Publications (2)

Publication Number Publication Date
MX2014002465A true MX2014002465A (es) 2014-08-01
MX357556B MX357556B (es) 2018-07-13

Family

ID=46642515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002465A MX357556B (es) 2011-09-12 2012-08-03 Composiciones acuosas que comprenden arbekacina.

Country Status (15)

Country Link
US (1) US9511143B2 (es)
EP (2) EP2567691B1 (es)
JP (1) JP6072801B2 (es)
KR (1) KR101944571B1 (es)
CN (1) CN103826611B (es)
AU (1) AU2012307661B2 (es)
BR (1) BR112014005538A2 (es)
CA (1) CA2844923C (es)
ES (2) ES2532667T3 (es)
MX (1) MX357556B (es)
PL (2) PL2567691T3 (es)
PT (2) PT2567691E (es)
RU (1) RU2604767C2 (es)
UA (1) UA113966C2 (es)
WO (1) WO2013037566A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014000540A (es) 2011-07-12 2014-05-01 Cardeas Pharma Corp Formulaciones de combinaciones de amecacina y forsfomicina y metodos y sistemas para el tratamiento de neumonia asociada a ventilacion mecanica (vap) y traqueobronquitis asociada a ventilacion mecanica (vat).
WO2014192848A1 (ja) 2013-05-30 2014-12-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 アルベカシン誘導体、並びにその製造及び利用
WO2015031405A1 (en) 2013-08-26 2015-03-05 Cardeas Pharma Corporation Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
AU2016252885B2 (en) * 2015-04-22 2021-05-20 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating mycobacteria infections and lung disease
LT3463281T (lt) * 2016-05-31 2022-09-26 Spexis Ag Beta-plaukų segtuko formos peptidomimetikai su elastazės inhibitoriniu aktyvumu ir aerozolinės jo dozavimo formos
CN110483597A (zh) * 2019-09-07 2019-11-22 常州方圆制药有限公司 阿贝卡星盐酸盐的假多晶型、其制备方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029882A (en) * 1974-03-19 1977-06-14 Schering Corporation Selective acylation of the C-1 amino group of aminoglycoside antibiotics
JPS5651499A (en) 1979-10-01 1981-05-09 Meiji Seika Kaisha Ltd Aminoglycoside derivative and its preparation
JPS58134099A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質の精製法
JP3215759B2 (ja) * 1993-09-09 2001-10-09 財団法人微生物化学研究会 耐性菌に有効な５−置換−２″−アミノ−２″−デオキシアルベカシンとその製造法
JP3215732B2 (ja) * 1992-11-27 2001-10-09 財団法人微生物化学研究会 耐性菌に有効なジベカシン誘導体またはアルベカシン誘導体とそれらの製造法
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JP3213687B2 (ja) * 1995-10-09 2001-10-02 財団法人微生物化学研究会 アルベカシンと（−）−シス−１，２−エポキシプロピルホスホン酸との付加塩およびその製造法、ならびに抗菌剤
JP2001161789A (ja) * 1999-12-07 2001-06-19 Sawai Pharmaceutical Co Ltd 水性注射剤
ATE267591T1 (de) 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
NZ546821A (en) 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
DK2266534T3 (da) * 2004-05-17 2013-01-14 Gilead Sciences Inc Aerosoliseret fosfomycin/tobramycin-kombination til behandling af cystisk fibrose
DE102005038619A1 (de) 2005-08-16 2007-02-22 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments
WO2008043825A2 (en) * 2006-10-11 2008-04-17 Laboratoires Smb S.A. Pharmaceutical anti-infective composition for inhalation.
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
DE102007056462B4 (de) 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
CN101575354B (zh) 2009-05-26 2013-03-13 北京化工大学 阿贝卡星及其中间体地贝卡星的合成方法
BR112012014405B1 (pt) * 2009-12-14 2019-05-14 Chiesi Farmaceutici S.P.A. Formulação de pó seco, micropartícula, cápsula para uso com um inalador de pó seco, método para preparação de uma micropartícula e uso de uma micropartícula
JP5651499B2 (ja) 2011-03-01 2015-01-14 カヤバ工業株式会社 フロントフォーク用の姿勢維持具

Also Published As

Publication number Publication date
US20140343005A1 (en) 2014-11-20
PL2755635T3 (pl) 2016-03-31
CA2844923C (en) 2019-04-30
ES2555462T3 (es) 2016-01-04
MX357556B (es) 2018-07-13
ES2532667T3 (es) 2015-03-30
JP2014526481A (ja) 2014-10-06
AU2012307661B2 (en) 2017-02-02
EP2567691B1 (en) 2014-12-24
PT2755635E (pt) 2016-02-10
AU2012307661A1 (en) 2014-02-20
PL2567691T3 (pl) 2015-05-29
KR20140090598A (ko) 2014-07-17
RU2014114512A (ru) 2015-10-27
RU2604767C2 (ru) 2016-12-10
CA2844923A1 (en) 2013-03-21
PT2567691E (pt) 2015-04-09
KR101944571B1 (ko) 2019-01-31
EP2755635B1 (en) 2015-10-14
CN103826611A (zh) 2014-05-28
CN103826611B (zh) 2016-10-19
EP2567691A1 (en) 2013-03-13
UA113966C2 (xx) 2017-04-10
BR112014005538A2 (pt) 2017-03-21
JP6072801B2 (ja) 2017-02-01
WO2013037566A1 (en) 2013-03-21
US9511143B2 (en) 2016-12-06
EP2755635A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP2749277A3 (en) Combination of glycopyrronium and vilanterol
EA201390049A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
BR112013013429A2 (pt) composição, método de prevenção ou tratamento de distúrbio ou doença de controle da respiração, e, método de prevenção de desestabilização ou estabilização do ritmo respiratório
MX2014002465A (es) Composiciones acuosas que comprenden arbekacina.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
MX2015010829A (es) Compuestos terapeuticos y sus usos.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
MX2013011772A (es) Aclidinio para uso en la mejora de la calidad del sueño en pacientes respiratorios.
TW200731976A (en) Use of tiotropium salts in the treatment of moderate persistent asthma
PT2454266E (pt) Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
IN2014MN02133A (es)
MX2014003867A (es) Tratamiento de rinitis.
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
UA89921C2 (ru) Способ лечения хронического обструктивного заболевания лёгких при помощи месалазина
WO2012095726A8 (en) Pharmaceutical combination containing glucosamine salts and paracetamol for the treatment of osteoarthritis
MX2012014342A (es) Preparacion de una sal de levalbuterol.
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: MEIJI SEIKA PHARMA CO., LTD.

FG Grant or registration